News
HKUMed has achieved a significant breakthrough in developing needle-free, live-attenuated influenza vaccines with broad protection against human and avian virus subtypes. The novel innovations ...
Recombinant (RIV4) and live attenuated influenza vaccine (LAIV4; intranasal vaccine) will be available in quadrivalent formulations," ACIP explains in the recommendations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results